Foghorn Therapeutics Inc. (FHTX)
FHTX moved a median of +0.17% 30 minutes after news, and -0.42% by the close. How FHTX actually reacts to news — the realized, point-in-time move the market made, measured across 238 labeled events over the last three years with zero look-ahead.
FHTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 30% | 235 |
| 30-min | +0.17% | 53% | 238 |
| 60-min | +0.17% | 54% | 238 |
| to close | -0.42% | 44% | 237 |
| Middle 50% of FHTX reactions | -1.47% to +2.00% |
|---|---|
| Median reaction (30-min) | +0.17% |
| Measured reactions | 238 |
Half of all Foghorn Therapeutics Inc. news events land between -1.47% and +2.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How FHTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 23 | +0.21% | 61% | +4.08% |
| Rating reiterations | 35 | -0.05% | 46% | +1.55% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how FHTX ranks against every other measured name →
That’s how FHTX usually reacts — get an email when it moves on news →Email me when FHTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to FHTX's baseline. Nothing else.
Recent FHTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Encourages Foghorn Therapeutics Inc. (FHTX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | — | — | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Foghorn Therapeutics Inc. (FHTX) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.00% | -1.33% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Foghorn Therapeutics Inc. (FHTX) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.26% | -0.53% | |
| Foghorn Therapeutics Inc. (FHTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.79% | -1.33% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Foghorn Therapeutics Inc. (FHTX) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -2.38% | |
| FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +0.00% | -1.51% | |
| Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities | Press release | GlobeNewswire | -10.10% | +40.38% | |
| Form 8-K Foghorn Therapeutics For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | -10.10% | +40.38% | |
| Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update | Press release | GlobeNewswire | +0.00% | +10.08% | |
| Form 10-Q Foghorn Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +10.08% | |
| Form 8-K Foghorn Therapeutics For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +10.08% | |
| Form 8-K Foghorn Therapeutics For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +1.22% | -1.47% | |
| Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 | Press release | GlobeNewswire | +0.27% | +0.00% | |
| Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May | Press release | GlobeNewswire | +2.31% | -1.85% | |
| Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update | Press release | GlobeNewswire | -1.50% | -10.26% | |
| Form 10-Q Foghorn Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.50% | -10.26% | |
| Form 8-K Foghorn Therapeutics For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -10.26% | |
| Form ARS Foghorn Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -0.42% | |
| Form DEF 14A Foghorn Therapeutics For: Jun 24 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -0.42% | |
| Form DEFA14A Foghorn Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -0.42% | |
| Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | +0.57% | +3.26% | |
| Form 8-K Foghorn Therapeutics For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | +0.57% | +3.26% | |
| Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | -2.70% | -0.42% | |
| Form S-8 Foghorn Therapeutics | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -7.22% | |
| Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook | Press release | GlobeNewswire | -2.59% | — | |
| Form 10-K Foghorn Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.59% | -12.14% | |
| Form 8-K Foghorn Therapeutics For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | -2.59% | -12.14% | |
| Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | -1.56% | |
| Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer | Press release | GlobeNewswire | -0.52% | +0.35% | |
| Form 8-K Foghorn Therapeutics For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | -0.52% | +0.35% | |
| Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit | Press release | GlobeNewswire | +0.68% | -2.90% | |
| Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium | Press release | GlobeNewswire | -0.45% | -4.54% | |
| Form 8-K Foghorn Therapeutics For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +1.94% | +17.71% | |
| Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 | Press release | GlobeNewswire | +1.94% | +17.71% | |
| Form 8-K Foghorn Therapeutics For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | +0.88% | +0.44% | |
| Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference | Press release | GlobeNewswire | +0.65% | +2.61% | |
| Form 8-K Foghorn Therapeutics For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | +1.80% | -0.45% | |
| Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update | Press release | GlobeNewswire | +2.83% | +12.99% | |
| Form 10-Q Foghorn Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.83% | +12.99% | |
| Form 8-K Foghorn Therapeutics For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +2.83% | +12.99% | |
| Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences | Press release | GlobeNewswire | -2.73% | -4.32% | |
| Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs | Press release | GlobeNewswire | +0.00% | +2.38% | |
| Form 8-K Foghorn Therapeutics For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.38% | |
| Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit | Press release | GlobeNewswire | -3.56% | -4.22% | |
| Form 8-K Foghorn Therapeutics For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | -0.19% | +0.00% | |
| Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences | Press release | GlobeNewswire | -0.09% | -2.17% | |
| Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering | Press release | PR Newswire | — | -1.26% | |
| Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update | Press release | GlobeNewswire | -1.91% | -4.40% | |
| Form 10-Q Foghorn Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.91% | -4.40% | |
| Form 8-K Foghorn Therapeutics For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | -4.40% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the FHTX section they belong to.
Where else FHTX is measured.
FHTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Foghorn Therapeutics Inc.'s median reaction calculated?
Every labeled FHTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 238 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of FHTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does FHTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.